FDA to Review Increased Health Risks Associated with Aranesp, Epogen and Procrit

The FDA recently announced that it would review the safety of widely used anemia drugs sold by Amgen and Johnson & Johnson: Aranesp, Epogen, and Procrit. This announcement comes in the wake of a finding that high doses of the anemia drug Aranesp might lead to an increased risk of heart attacks, blood clots and strokes in its users. A recently published commentary in The New England Journal of Medicine stated that the new findings raise “major concerns” about drugs used to treat anemia caused by chronic kidney disease.

The FDA also plans to consider new ways to control the doses of these drugs. Since 2007, the FDA has held three advisory panel meetings regarding these drugs, and has changed the labels accordingly to warn of risks associated with them.

Some experts have called for additional caution due to the new commentary from the New England Journal Medicine. Dr Ajay Singh of Brigham Women’s Hospital and Harvard Medical School has stated that avoiding the use of drugs in kidney patients not undergoing dialysis “is now the soundest approach.”

Contact an Experienced Personal Injury Attorney

Personal injury attorneys at Pintas Law Firm are currently representing clients who suffered injuries as a result of taking anemia drugs such as Aranesp, Epogen, and Procrit. If you have suffered a heart attack, a stroke, or other complication involving blood clots following a course of treatment with these drugs, contact us for a free consultation.

Free Consultation
  • Please enter your first name.
  • Please enter your last name.
  • Please enter your email.
    This isn't a valid email address.
  • Please enter your phone number.
    This isn't a valid phone number.
  • Please make a selection.
  • Please make a selection.
  • Please enter your message.